Research programme: anthrax toxin-based cancer therapeutic - Sanofi/Kirin
Alternative Names: Research programme: anthrax toxin - Sanofi/KirinLatest Information Update: 31 Mar 2022
At a glance
- Originator Genzyme Corporation; Kirin Brewery
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 May 2006 No development reported - Preclinical for Cancer in Japan (unspecified route)
- 04 May 2006 No development reported - Preclinical for Cancer in USA (unspecified route)
- 19 Apr 2004 Preclinical trials in Cancer in Japan (unspecified route)